The new system is expected to expedite research reviews without changing safety standards.
U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announced the agency has launched a pilot program that allows regulators to monitor clinical trial data in real time using artificial intelligence (AI) and cloud-based systems. The initiative includes early-stage trials conducted by pharmaceutical companies and, the commissioner said, “challenge[s] the assumption that it takes 10 to 12 years for a new drug to come to market.”
Commissioner Makary explained that the pilot will allow the agency “a direct data feed from a clinical trial, where the FDA will see what is happening, in the cloud, with the predefined clinical endpoints and any other signals investigators and regulators decide are valuable.”
“The goal here is to sort of get to a regulatory decision in a faster timeline, without compromising any safety,” said FDA Chief Artificial Intelligence Officer Jeremy Walsh. “We are reimagining what information we need and when we need it in order to make a decision.”
The agency also issued a request for public input on expanding the use of real-time trial methods. Alongside the pilot, the FDA reported broader technology upgrades, including consolidating data systems and increasing the use of AI tools across its workforce.
As the Lord Leads, Pray with Us…
- For FDA Commissioner Makary and FDA Chief AI Officer Walsh as they implement these innovations.
- For FDA researchers, clinicians, and trial participants as they engage in the development and monitoring process.
- For HHS and FDA officials to be discerning as they seek more efficient and effective means to monitor trial data and enhance the approval process for pharmaceuticals.
Sources: Gov Exec, Department of Health and Human Services
